Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets

Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets

Publication: Drug Dev Ind Pharm
Software: GastroPlus®

The generic drug product DRL ABC is an Extended Release (ER) Tablet manufactured by Dr. Reddy’s Laboratories Limited and have multi point dissolution as part of release specification.

Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions

Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions

Authors: Deb S, Reeves AA
Software: GastroPlus®

Remdesivir, a drug originally developed against Ebola virus, is currently recommended for patients hospitalized with coronavirus disease of 2019 (COVID-19).

Relationship Between Pimavanserin Exposure and Negative Symptoms in Patients With Schizophrenia: Data Analysis From the Phase 2 ADVANCE Study

Relationship Between Pimavanserin Exposure and Negative Symptoms in Patients With Schizophrenia: Data Analysis From the Phase 2 ADVANCE Study

Conference: ASCP

Negative symptoms in schizophrenia are associated with poor psychosocial function and long-term outcomes yet no pharmacological treatments are currently approved in the United States to treat...

Oral APX3330 treatment reduces L-CNV lesions in preclinical mouse model and confirms Phase 2 DR/DME clinical dose with sufficient distribution to human retina using PBPK modeling

Oral APX3330 treatment reduces L-CNV lesions in preclinical mouse model and confirms Phase 2 DR/DME clinical dose with sufficient distribution to human retina using PBPK modeling

Publication: Invest. Ophthal. and Vis. Sci.
Therapeutic Areas: Ophthalmology

APX3330 is a small molecule inhibitor of Ref-1, a target involved in key vascular and inflammatory ocular disease processes including diabetic retinopathy (DR), diabetic macular edema (DME) and wetAMD.

Particle Deposition in Respiratory Tract: Where are the Limits?

Particle Deposition in Respiratory Tract: Where are the Limits?

Publication: CMBEBIH 2021
Software: GastroPlus®

In last two decades in silico biopharmaceutics modelling has become increasingly important in all stages of drug development.